line

Now tell me what research has been carried out on NicoBloc?

Smoking Facts

50% of young deaths, below age 65, from heart disease are caused by smoking

NicoBloc has completed research at prestigious centers that back the efficacy of its component as an element reducing the ingestion of nicotine and tar:

- Stillwell & Gladding Laboratories - University of New York
Report No 93-1342, 19 April 1993. This demonstrated a maximum reduction of 99.2% in tar and 98.1% in nicotine in 2 leading brands of cigarette nozzle

- University of Pennsylvania, New York
A preliminary clinical study examined the efficacy of NicoBloc as a product for giving up smoking, combining a motivational protocol with a non-pharmacological component.

- The National Institute on Drug Abuse, Division of Intramural Research, Addiction Research Centre, Baltimore, USA
A study showed that NicoBloc reduced the exposure to nicotine and other constituents of tobacco smoke.

- Rosen Programme
This is a study carried out by the company that manufactures NicoBloc (Rosen Holdings Ltd.) in Ireland and the United Kingdom between 1995 and 2001, in which 680 smokers in companies and organisations took part in a project for breaking the tobacco habit using NicoBloc.



Comment from Rosen Programme/NicoBloc personnel

The published evidence clearly shows that use of the NicoBloc fluid reduces the delivery of tars and nicotine. However, there are other important elements of the NicoBloc programme which also contribute to the stopping attempt. These include behavioural modification (applying the fluid to the cigarettes, breaking the pack-to-mouth routine), goal-setting (record keeping and planned reductions), psychological shift (making decisions to smoke rather than trying not to smoke) and feedback (sight of the accumulated tars on the filter end, unpleasant taste if the accumulated tar comes into contact with the tongue, increased sense of wellbeing as cigarette consumption decreases and, finally, use of the nicotine test kit to confirm the absence of nicotine).

Experience with the Rosen Programme suggests that attempting to reduce smoking more quickly, to stop in less than 6 weeks, makes the stop attempt more difficult. We believe that, for many would-be stoppers, the combination of NicoBloc fluid and slow reduction in the number of cigarettes smoked result in decreasing the consumption of nicotine sufficiently slowly that cravings and other withdrawal symptoms either do not occur or are mild enough to be tolerated. In conjunction with the positive psychological and behavioural aspects of the programme, NicoBloc is an effective stopping aid.